Back to Search
Start Over
The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques
- Source :
- Parkinsonism & Related Disorders. 78:151-157
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
-
Abstract
- Background Long-term treatment of Parkinson's disease (PD) with l -DOPA typically leads to development of l -DOPA induced dyskinesia (LID). Amantadine, an NMDA antagonist, attenuates LID, but with limited efficacy and considerable side-effects. NLX-112 (also known as befiradol or F13640), a highly selective and efficacious 5-HT1A receptor agonist, reduced LID when tested in rodent and marmoset models of PD. Methods The effects of NLX-112 (0.03, 0.1 and 0.3 mg/kg PO) on established LID evoked by acute challenge with l -DOPA (27.5 ± 3.8 mg/kg PO) were assessed in MPTP-treated cynomolgus macaques. Amantadine (10 mg/kg PO) was tested as a positive control. Plasma exposure of NLX-112 (0.1 mg/kg PO) was determined. Results NLX-112 significantly and dose-dependently reduced median LID levels by up to 96% during the first hour post-administration (0.3 mg/kg). Moreover, NLX-112 reduced the duration of ‘bad on-time’ associated with disabling LID by up to 48% (0.3 mg/kg). In contrast, NLX-112 had negligible impact on the anti-parkinsonian benefit of l -DOPA. NLX-112 exposure peaked at ~50 ng/ml at 30 min post-administration but decreased to ~15 ng/ml at 2h. Amantadine reduced by 42% ‘bad on-time’ associated with l -DOPA, thereby validating the model. Conclusion These data show that, in MPTP-lesioned cynomolgus macaques, NLX-112 exerts robust anti-dyskinetic effects, without reducing the anti-parkinsonian benefit of l -DOPA. These observations complement previous findings and suggest that selective and high efficacy activation of 5-HT1A receptors by NLX-112 may constitute a promising approach to combat LID in PD, providing an alternative for patients in whom amantadine is poorly tolerated or without useful effect.
- Subjects :
- 0301 basic medicine
Agonist
business.industry
medicine.drug_class
MPTP
Amantadine
Pharmacology
Befiradol
03 medical and health sciences
chemistry.chemical_compound
030104 developmental biology
0302 clinical medicine
Neurology
chemistry
medicine
5-HT1A receptor
NMDA receptor
Neurology (clinical)
Geriatrics and Gerontology
Receptor
business
NLX
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- ISSN :
- 13538020
- Volume :
- 78
- Database :
- OpenAIRE
- Journal :
- Parkinsonism & Related Disorders
- Accession number :
- edsair.doi...........ac9d47b64548e3a63c4c1d814b6b1cf9
- Full Text :
- https://doi.org/10.1016/j.parkreldis.2020.08.009